Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Documenti analoghi

• Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
  di: Miner, Jeffrey, et al.
  Pubblicazione: (2016)
• The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
  di: Baumgartner, Scott, et al.
  Pubblicazione: (2018)
• Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
  di: Shen, Zancong, et al.
  Pubblicazione: (2015)
• Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
  di: Terkeltaub, Robert, et al.
  Pubblicazione: (2019)
• In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters
  di: Shen, Zancong, et al.
  Pubblicazione: (2016)